Baltimore wins $266 million in opioid case against distributors
By Brendan Pierson
Nov 13 (Reuters) -The city of Baltimore won $266 million in its lawsuit accusing top drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction in the U.S., and is expected to seek billions more in the next phase of the case.
A six-person jury in the Circuit Court for Baltimore found McKesson responsible for $192 million and Cencora for $74 million on Tuesday following a nearly two-month trial. The amount represents damages compensating the city for harms the companies were found to have caused.
Baltimore, which has been hit hard by the opioid crisis, opted out of large national opioid settlements in recent years in the hope of winning more money on its own. In 2022, Baltimore recorded 904 opioid overdose deaths, out of a total population of about 569,000, while the national opioid overdose death rate was about 25 per 100,000.
Next month, the city is expected to ask Judge Lawrence Fletcher-Hill for about $9 billion from the companies to pay for the cost of addressing the opioid crisis going forward. That is a legal remedy known as abatement, and is distinct from civil damages.
Baltimore accuses Cencora, formerly called AmerisourceBergen, and McKesson of ignoring red flags that opioids they supplied were being diverted into illegal channels. The companies deny the claim.
"Justice was done," said Bill Carmody, a lawyer for Baltimore. "The jury's verdict is an important step toward helping Baltimore recover so that it can continue to be one of the best cities in America and a place where all of its citizens can be healthy and succeed."
Both companies said they would seek to have the verdict overturned. McKesson in a statement said that the verdict "fundamentally misunderstands McKesson's limited role as a pharmaceutical distributor."
Cencora said it "frays the legal and ethical tightrope the company is being asked to walk between providing access to necessary medications and acting to prevent diversion of controlled substances."
Baltimore is one of more than 3,000 local, Native American tribal and state governments across the country that have filed similar lawsuits against drugmakers, distributors and pharmacies over the opioid crisis. The vast majority of those cases have been settled through nationwide agreements, which now total about $46 billion.
With Tuesday's verdict, which comes after a series of settlements with other companies including Walgreens WBA.O and Johnson & Johnson JNJ.N, Baltimore has now obtained more than $668 million in verdicts and settlements.
McKesson supplied about half of Baltimore's opioids between 2006 and 2019, according to U.S. government data. In 2017, it reached a $150 million settlement with the U.S. Department of Justice, under which it admitted that it had failed in its duty to prevent illegal drug sales nationwide.
Cencora is also currently facing a civil lawsuit by the Justice Department over its alleged role in the opioid crisis.
More than 800,000 people in the United States died of opioid overdoses from 1999 through 2023, according to data from the U.S. Centers for Disease Control and Prevention.
Reporting By Brendan Pierson in New York, Editing by Alexia Garamfalvi and Bill Berkrot
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
